StonvexLoading…
StonvexStonvexStonvexCore line items from AVNT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-30 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $908.41M | $847.40M | $3.26B | $2.50B | $1.69B |
Operating Income | Not available | $95.80M | $203.50M | $163.90M | $96.80M |
Net Income | Not available | $55.70M | $81.90M | $65.00M | $32.40M |
EPS (Diluted) | $0.90 | $0.61 | $0.89 | $0.71 | $0.35 |
Total Assets | Not available | $5.94B | $6.03B | $6.06B | $6.13B |
Total Liabilities | Not available | Not available | Not available | Not available | Not available |
Cash & Equivalents | Not available | $427.60M | $510.50M | $445.60M | $474.50M |
Free Cash Flow OCF − CapEx | Not available | $-53.50M | $195.00M | $69.60M | $22.20M |
Shares Outstanding | Not available | 91.90M | 91.80M | 91.80M | 91.80M |